You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

361 Results
Guidelines and Advice
Status: Current
ID: GL-END-C50-35
Aug 2023
Guidelines and Advice
Status: Current
ID: GL-END 3-25
Nov 2023
Guidelines and Advice
Status: Current
ID: PET 2023-1
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT
ODB Limited Use
    lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
lenalidomide,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Guidelines and Advice
Status: Current
ID: 7-A-2022-1-17v3
Version: 3
Oct 2023
Drug
Other Name(s): Camptosar®
Quick Link(s): Drug Monograph, Patient Info Sheet
Apr 2023
Drug
Other Name(s): Gemzar®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 2023
Drug
Other Name(s): Erbitux®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2023
Guidelines and Advice
Status: Archived
ID: 20-3
Jan 2016
Guidelines and Advice
Status: Current
ID: 17-4
Version: 2
Nov 2016
Statistical Reports
Jun 2016
Statistical Reports
Apr 2023

Pages